NCT00750698 2023-07-06A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on ErlotinibSyndax PharmaceuticalsPhase 2 Terminated8 enrolled 6 charts